

Catumaxomab

Cat. No.:	HY-P9954
CAS No.:	509077-98-9
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers ^{[1][2]} .
In Vitro	Catumaxomab (0-5 ng/mL; 3-7 days) strongly inhibits the growth of FaDu tumor spheroids in coculture with PBMC with a dose-dependent manner ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Mansoor M. Amiji, et.al. Chapter Two - Innate and adaptive immunity in cancer. Cancer Immunology and Immunotherapy. Academic Press, 2022, Pages 19-61.
- [2]. Hirschhaeuser F, et.al. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. 2010 Nov;59(11):1675-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA